| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 0.00 | 100.0% | 100.0% |
| Total Income | 0.00 | 100.0% | 100.0% |
| Expenditure | 0.12 | 63.3% | 58.3% |
| PBT | -0.12 | 242.4% | 208.0% |
| Net Profit | -0.12 | 242.4% | 208.0% |
| OPM | — | ||
| NPM | — | ||
| EPS | 0.11 | 37.5% | 0.0% |
Hindustan Bio Sciences FY26 Revenue at ₹73.71 Cr
30 May 2026 · 30 May, 7:04 pm
Summary
Hindustan Biosciences Ltd. reported a challenging financial performance for the fourth quarter and full financial year ended March 31, 2026. Total revenue for Q4 FY26 drastically fell by nearly 100% year-on-year to ₹0.02 lakhs, with revenue from operations recorded at ₹0.00 lakhs. For the full financial year 2026, the company's total revenue declined by approximately 9.37% to ₹73.71 lakhs from ₹81.33 lakhs in FY25. Additionally, the Board approved the re-appointment of Mr. GBK Viswanadham as the Internal Auditor for the upcoming financial year 2026-27, and the statutory auditors provided an unmodified opinion on the financial statements.
Key Highlights
- 1
Hindustan Biosciences Ltd. reported a significant decline in total revenue for the fourth quarter ended March 31, 2026, dropping to ₹0.02 lakhs from ₹38.79 lakhs in the same quarter last year.
- 2
Revenue from operations for Q4 FY26 was ₹0.00 lakhs, representing a 100% year-on-year decrease compared to ₹37.53 lakhs in Q4 FY25.
- 3
For the full financial year 2026, total revenue decreased by approximately 9.37% to ₹73.71 lakhs, down from ₹81.33 lakhs in FY25.
- 4
Purchases of stock-in-trade for the financial year 2026 amounted to ₹44.90 lakhs, a decrease from ₹49.39 lakhs in the previous fiscal year.
- 5
The Board approved the re-appointment of Mr. GBK Viswanadham as an Internal Auditor for the financial year 2026-27.
- 6
The statutory auditors, M/s. VASG & ASSOCIATES, issued an unmodified opinion on the Standalone Financial Statements for the financial year ended March 31, 2026.
Informational and educational content only. Not investment advice.